Compare Barrick Gold Corp (B) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barrick Gold Corp vs TG Therapeutics Inc — how do they compare? Barrick Gold Corp trades at $41.25 (market cap $65.92B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Barrick Gold Corp is far larger — about 8.6× TG Therapeutics Inc's market cap, and Barrick Gold Corp pays a 1.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| B | TGTX | |
|---|---|---|
Market Cap | $65.92B | $7.64B |
Sector | Basic Materials | Health |
52-Week High | $52.97 | $59.06 |
52-Week Low | $23.50 | $26.94 |
Enterprise Value | $64.67B | $7.84B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barrick Mining (B) trades at $41.56, up 1.59% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 10.37, net income margin of 31.6%, and consistent earnings beats. Recent developments include a $1.95 billion settlement with Newmont and plans for a North American gold IPO, driving positive sentiment. Technical indicators show bullish moving averages with support at $40 and resistance at $41.
Outlook remains positive with 66.7% analyst buy ratings and a $49.83 consensus target, offering 20% upside. Key risks include gold price volatility and execution of the IPO. Strong cash flow growth and debt reduction support the bullish case, though investors should monitor commodity price trends and operational execution.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barrick Gold Corp
Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
